452
Participants
Start Date
May 31, 2013
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
THR-184
THR-184 is a synthetic oligopeptide administered intravenously.
Placebo
A normal saline solution identical in appearance to the active drug solution
Columbia University, New York
St. Peter's Hospital, Albany
Suburban Hospital, Bethesda
John Hopkins University, Baltimore
Cardiothoracic Surgical Associates, Richmond
Duke University Medical Center, Durham
Durham VA Medical Center, Durham
River City Clinical Research, Jacksonville
University of Alabama-Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Erlanger Health System, Chattanooga
Memorial Hospital, Chattanooga
The Ohio State University Medical Center, Columbus
Lindner Research Center-Christ Hospital, Cincinnati
Indiana Heart-St. Vincent Medical Group, Indianapolis
Indiana Ohio Heart, Fort Wayne
Covenant Medical Center, Saginaw
Cardiac and Vascular Research Center of Northern Michigan, Petoskey
Advocate Christ Medical Center, Oak Lawn
University of Chicago, Chicago
Washington University, St Louis
Baylor University Medical Center, Soltero Cardiovascular Research Center, Dallas
University of Texas, Houston, Houston
University of Southern California, Los Angeles
Harbor - University of California Los Angeles Medical Center, Torrance
Stanford University, Stanford
Danbury Hospital, Danbury
Maine Medical Center, Portland
Massachusetts General Hospital, Boston
Baystate Medical Center, Springfield
St. Joseph's Regional Medical Center, Paterson
Foothills Medical Centre, Calgary
St-John Regional Hospital Facility, Saint John
Hamilton Health Sciences Corporation, Hamilton
University of Ottawa Heart Institute, Ottawa
St. Michael's Hospital, Toronto
Institut de Cardiologie de Montréal, Montreal
Centre hospitalier de l'université de Montréal(CHUM)- Hôtel-Dieu, Montreal
MUHC - Royal Victoria Hospital, Montreal
Sacre Cœur Hospital, Montreal
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec
Thrasos Innovation, Inc.
INDUSTRY